The agency updated its list of recommended influenza virus strains that manufacturers should include in vaccines for the autumn 2019 season.
On May 20, 2019, the European Medicines Agency (EMA) announced that it updated the European Union list of recommendations for the influenza virus strains that manufacturers should include in vaccines for the prevention of seasonal influenza starting in autumn 2019.
The recommendations contain a decision on suitable H1N1 and H3N2 viruses for seasonal live attenuated influenza vaccines (LAIV). The list of reagents for vaccine standardization has also been updated.
Details such as the specific virus strains to be included are available in the updated 2019/2020 recommendations, which were issued by EMA's Biologics Working Party ad-hoc Influenza Working Group. The ad-hoc Influenza Working Group initially made recommendations for the 2019/2020 flu vaccines on April 1, 2019 and first updated its recommendations on April 10, 2019. The list is developed on the basis of recommendations by the World Health Organization.
Applications to change the composition of centrally authorized flu vaccines are due by June 17, 2019.
Source: EMA
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.